Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., Bonnefoi, H., Krop, I., Liu, T., Pieńkowski, T., Toi, M., Wilcken, N., Andersson, M., Im, Y., Tseng, L. M., Lueck, H., Colleoni, M., Monturus, E., Sicoe, M., Guillaume, S., Bines, J., Gelber, R. D., Viale, G., Thomssen, C., & , (2021). adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of clinical oncology, 39(13), 1448–1457. http://access.bl.uk/ark:/81055/vdc_100150610789.0x00003b